IRVINE, Calif.—With net sales of $1,790.7 million for the third quarter ended Sept. 30, 2014, a 17.2 percent increase over net sales for the third quarter of 2013, Allergan, Inc. (NYSE: AGN) reported its “strongest increase in absolute dollar sales in any quarter in our history,” according to David E.I. Pyott, chairman and CEO, in a statement released by Allergan on Monday, Oct. 27, 2014.

Net earnings for Q3 2014 were $313.4 million, a 4.2 percent increase when compared with $300.8 million for the third quarter of 2013.

Allergan’s eyecare pharmaceuticals (which include Refresh and Restasis for dry eye and Alphagan, Combigan, and Lumigan for glaucoma, among other products) generated net sales of $818.8 million in Q3 2014, up 14.2 percent from the $717.1 million in eyecare pharmaceutical product sales during the third quarter of 2013.

Restasis alone generated sales of $273.3 million during Q3 2014, a 14.2 percent increase when compared with $239.3 million in Restasis sales in Q3 2013. Allergan sold $297.6 million in total glaucoma products in Q3 2014, up 11.1 percent when compared with the $267.9 million in glaucoma products sold in Q3 2013. Sales of Allergan’s eyelash-growth pharmaceutical product, Latisse, were down 8.2 percent from $24.4 million in Q3 2013 to $22.4 million in Q4 2014.

Other highlights of the quarter include: On Sept. 29, 2014, Allergan announced that the U.S. Food and Drug Administration removed the limitations on the indication for Ozurdex (dexamethasone intravitreal implant) 0.7mg, a sustained-release biodegradable steroid implant, for the treatment of diabetic macular edema (DME). Ozurdex was originally approved in June as a treatment for DME in patients who are pseudophakic (have an artificial lens implant following cataract surgery) or who are phakic (have their natural lens) and are scheduled for cataract surgery.